Navigation Links
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer

Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer.

Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer. The companies also confirmed that they are planning a company- sponsored Phase 3 study of Nexavar in the adjuvant treatment of HCC following the complete removal of early stage liver cancer.

The sNDA submission is based on positive data from the international, Phase 3, placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial which demonstrated that Nexavar extended overall survival by 44 percent in patients with HCC (HR=0.69; p=0.0006) versus placebo.

There were no significant differences in serious adverse event rates between the Nexavar and placebo-treated groups with the most commonly observed adverse events in patients receiving Nexavar being diarrhea and hand-foot skin reaction. Currently, there are no FDA-approved drug therapies that significantly extend survival of patients with liver cancer.

"These results are particularly meaningful considering that death rates from liver cancer continue to increase," said Susan Kelley, M.D., vice president, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals. "After more than 100 clinical studies of many agents over three decades.

Nexavar is the first drug therapy to demonstrate a significant survival benefit for patients with HCC, and, if approved, may fulfill a serious unmet need with a manageable toxicity profile."

HCC, the most common form of liver cancer, is responsible for about 90 percent of the primary liver cancers in adults. It is the fifth most common cancer in the world and the third leading cause of cancer-related deaths globally.

Over 600,000 cases of HCC are diagnosed globally each year(about 19,000 in the United States and 32,000 in the European Union) and in 2002 approximately 600,000 people (about 13,000 Americans and 57,000 Europeans) died of HCC.

"This filing exemplifies our commitment to providing valuable therapeutic options for significant unmet needs in cancer treatment," said Hank Fuchs, M.D., executive vice president and chief medical officer of Onyx.

"We believe that Nexavar will become the reference standard of care in HCC, and will help advance our development program, which includes clinical trials studying Nexavar alone and in combination with other therapies across many different cancer types, including melanoma, non-small cell lung and breast cancer."




'"/>




Related medicine news :

1. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
2. Bayer Wins Positive Response For Marketing Its Cancer Drug
3. Genomatix Licensed By Bayer Healthcare
4. Bayer to Market Biocon Insulin in China
5. Test for Esophageal Reflux Licensed to Bayer by University
6. Recd Number of Abstracts Submitted for Sci Cong on Osteoporosis
7. MBBS Aspirants Get 90 Days To Submit Caste Validity Certificate
8. New Drug Application Submitted for Investigational Antibiotic Doripenem
9. New Supplemental Therapy for Common Jaw Disorder
10. Prostate Cancer Can Be Treated By Application Of LASER Technology
11. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... ... May 03, 2016 , ... Hydra Skin Sciences, a top-rated skincare company ... a revolutionary new anti-aging skin care product that integrates Snow Algae Powder ... sold over seventy-five thousand units worldwide within the first two months of release. , ...
(Date:5/3/2016)... ... , ... Dave Newberry, broker/owner of Newberry Realty, recently announced his office will ... on Friday, May 20. “We have raised over $1,000 for the table to support ... , PICC is a local Kent, WA, clinic that cares for drug-exposed babies and ...
(Date:5/2/2016)... ... 2016 , ... RNK Products, Inc. (RNK) is beta testing ... the stethoscope stream to go over the video conferencing audio channel. This ... , Remote auscultation involves two software elements on the PC: , 1)    Network transport ...
(Date:5/2/2016)... ... , ... ProElectric Cartoon is a package of 30 hand-drawn electrifying animations made ... of electric styles including zap, sizzles, and more. Easily alter the highlights, midtones, and ... rotation, and much more. ProElectric Cartoon’s simplistic style makes it the perfect complement for ...
(Date:5/2/2016)... Texas (PRWEB) , ... May 02, 2016 , ... Pets ... As a token of appreciation, pet owners celebrate National Pet Week, which falls on ... in 2016, remind pet owners to cherish the human-animal bond and recognize responsible pet ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... "Global Plastic Surgery Products Market 2016-2020" report ... ) , The global plastic surgery ... of 9.47% during the period 2016-2020. , ,The growing ... leading to the growth of the market. Lasers are ...
(Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology: